Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients

P Ryscavage, S Kelly, JZ Li, PR Harrigan… - Antimicrobial agents …, 2014 - Am Soc Microbiol
ABSTRACT A goal of HIV therapy is to sustain suppression of the plasma viral load below
the detection limits of clinical assays. However, widely followed treatment guidelines diverge …

British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in …

Writing Group, I Williams, D Churchill… - HIV …, 2014 - Wiley Online Library
1.4 Resource use 1.5 Implications for research 1.6 References 2.0 Recommendations and
auditable outcomes 2.1 Recommendations (GRADE) 2.1. 1 Patient involvement in decision …

Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART

RE Nettles, TL Kieffer, P Kwon, D Monie, Y Han… - Jama, 2005 - jamanetwork.com
ContextMany patients infected with human immunodeficiency virus type 1 (HIV-1) and
receiving highly active antiretroviral therapy experience intermittent episodes of detectable …

[HTML][HTML] Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection

D Yuan, M Li, Y Zhou, L Shi, J Lu, G Fu… - Journal of Virus Eradication, 2023 - Elsevier
Antiretroviral therapy (ART) aims to inhibit HIV replication, decrease CD4 T cell loss, and
immune function recovery in order to reduce the morbidity and mortality associated with the …

Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy

J Fleming, WC Mathews, RM Rutstein, J Aberg… - Aids, 2019 - journals.lww.com
Background: The clinical management of low-level viremia (LLV) remains unclear. The
objective of this study was to investigate the association of blips and LLV with virologic …

Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis

JT Grennan, MR Loutfy, DS Su… - Journal of Infectious …, 2012 - academic.oup.com
Abstract (See the editorial commentary by Taiwo and Bosch, on pages 1189–91.)
Background. The importance of human immunodeficiency virus (HIV) blip magnitude on …

Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors

H Liu, LG Miller, RD Hays, CE Golin, T Wu… - JAIDS Journal of …, 2006 - journals.lww.com
Background: Adherence to antiretroviral medications is critical to achieving HIV viral
suppression. Studies have been limited to cross-sectional analyses using measures that …

Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma

AO Pasternak, M de Bruin, S Jurriaans… - The Journal of …, 2012 - academic.oup.com
Background. Modern antiretroviral therapy (ART) regimens are widely assumed to forgive
modest nonadherence, because virological suppression in plasma is common at adherence …

Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy

AM Geretti, C Smith, A Haberl, A Garcia-Diaz… - Antiviral …, 2008 - journals.sagepub.com
Background We aimed to investigate the long-term virological outcomes of a cohort initially
showing good responses to first-line highly active antiretroviral therapy (HAART) with no …

[HTML][HTML] Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels

E Sörstedt, S Nilsson, A Blaxhult, M Gisslén… - BMC infectious …, 2016 - Springer
Background Many HIV-1-infected patients on suppressive antiretroviral therapy (ART) have
transiently elevated HIV RNA levels. The clinical significance of these viral blips is uncertain …